GNFT
Genfit S.A.
Biotechnology
Market Cap$448M
5Y Perf.+71.5%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
GNFT vs AKRO vs MDGL vs HALO
Revenue, margins, valuation, and 5-year total return — side by side.
AKRO
Akero Therapeutics, Inc.
Biotechnology
Market Cap$4.50B
5Y Perf.+113.8%
MDGL
Madrigal Pharmaceuticals, Inc.
Biotechnology
Market Cap$12.27B
5Y Perf.+401.9%
HALO
Halozyme Therapeutics, Inc.
Biotechnology
Market Cap$7.68B
5Y Perf.+177.3%
GNFT vs AKRO vs MDGL vs HALO — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | GNFT | AKRO | MDGL | HALO |
|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Biotechnology |
| Market Cap | $448M | $4.50B | $12.27B | $7.68B |
| Revenue (TTM) | $117M | $0.00 | $1.13B | $1.40B |
| Net Income (TTM) | $-16M | $-293M | $-309M | $317M |
| Gross Margin | 104.9% | — | 93.1% | 81.9% |
| Operating Margin | 0.4% | — | -27.7% | 58.4% |
| Forward P/E | 256.9x | — | — | 8.1x |
| Total Debt | $62M | $36M | $354M | $0.00 |
| Cash & Equiv. | $82M | $340M | $199M | $134M |
GNFT vs AKRO vs MDGL vs HALO — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
GNFT
AKRO
MDGL
HALO
| Stock | May 20 | Mar 26 | Return |
|---|---|---|---|
| Genfit S.A. (GNFT) | 100 | 171.5 | +71.5% |
| Akero Therapeutics,… (AKRO) | 100 | 213.8 | +113.8% |
| Madrigal Pharmaceut… (MDGL) | 100 | 501.9 | +401.9% |
| Halozyme Therapeuti… (HALO) | 100 | 277.3 | +177.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: GNFT vs AKRO vs MDGL vs HALO
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: HALO leads in 3 of 7 categories, making it the strongest pick for valuation and capital efficiency and profitability and margin quality. Genfit S.A. is the stronger pick specifically for recent price momentum and sentiment. AKRO and MDGL also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
GNFT
Genfit S.A.
The Growth Play
GNFT is the #2 pick in this set and the best alternative if growth exposure is your priority.
- Rev growth 134.6%, EPS growth 105.2%, 3Y rev CAGR -5.8%
- +110.6% vs HALO's -7.1%
Best for: growth exposure
AKRO
Akero Therapeutics, Inc.
The Income Pick
AKRO is the clearest fit if your priority is income & stability and sleep-well-at-night.
- beta 0.35
- Lower volatility, beta 0.35, Low D/E 4.9%, current ratio 19.38x
- Beta 0.35, current ratio 19.38x
- Beta 0.35 vs GNFT's 0.95, lower leverage
Best for: income & stability and sleep-well-at-night
MDGL
Madrigal Pharmaceuticals, Inc.
The Long-Run Compounder
MDGL is the clearest fit if your priority is long-term compounding.
- 39.2% 10Y total return vs HALO's 5.7%
- 432.1% revenue growth vs AKRO's -24.6%
Best for: long-term compounding
HALO
Halozyme Therapeutics, Inc.
The Value Play
HALO carries the broadest edge in this set and is the clearest fit for value and quality.
- Better valuation composite
- 22.7% margin vs MDGL's -27.3%
- 12.5% ROA vs AKRO's -29.1%, ROIC 73.4% vs -55.3%
Best for: value and quality
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | MDGL | 432.1% revenue growth vs AKRO's -24.6% |
| Value | HALO | Better valuation composite |
| Quality / Margins | HALO | 22.7% margin vs MDGL's -27.3% |
| Stability / Safety | AKRO | Beta 0.35 vs GNFT's 0.95, lower leverage |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | GNFT | +110.6% vs HALO's -7.1% |
| Efficiency (ROA) | HALO | 12.5% ROA vs AKRO's -29.1%, ROIC 73.4% vs -55.3% |
GNFT vs AKRO vs MDGL vs HALO — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
FY 2025
FY 2025
GNFT vs AKRO vs MDGL vs HALO — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLHALOLAGGINGMDGL
Who Leads Where
HALO leads in 3 of 6 categories
AKRO leads 1 • GNFT leads 0 • MDGL leads 0 • 1 tied
Explore the data ↓MDGLMadrigal Pharmaceutic…
0leads
GNFTGenfit S.A.
0leads
AKROAkero Therapeutics, I…
1leads
HALOHalozyme Therapeutics…
3leads
6 Total Categories
CATEGORYLEADERvs AKROvs GNFTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
HALO3/6
Valuation MetricsMultiples, price ratios, and targets
HALO3/5
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
HALO6/9
Total Returns1Y, 3Y, 5Y total returns with dividends
Tied
—
Risk & VolatilityBeta, volatility, and downside exposure
AKRO2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
HALO leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
HALO and AKRO operate at a comparable scale, with $1.4B and $0 in trailing revenue. HALO is the more profitable business, keeping 22.7% of every revenue dollar as net income compared to MDGL's -27.3%. On growth, MDGL holds the edge at +126.8% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | GNFTGenfit S.A. | AKROAkero Therapeutic… | MDGLMadrigal Pharmace… | HALOHalozyme Therapeu… |
|---|---|---|---|---|
| RevenueTrailing 12 months | $117M | $0 | $1.1B | $1.4B |
| EBITDAEarnings before interest/tax | $4M | -$318M | -$312M | $945M |
| Net IncomeAfter-tax profit | -$16M | -$293M | -$309M | $317M |
| Free Cash FlowCash after capex | -$47M | -$250M | -$272M | $645M |
| Gross MarginGross profit ÷ Revenue | +104.9% | — | +93.1% | +81.9% |
| Operating MarginEBIT ÷ Revenue | +0.4% | — | -27.7% | +58.4% |
| Net MarginNet income ÷ Revenue | -14.1% | — | -27.3% | +22.7% |
| FCF MarginFCF ÷ Revenue | -40.4% | — | -24.1% | +46.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | -41.8% | — | +126.8% | +51.6% |
| EPS Growth (YoY)Latest quarter vs prior year | -140.0% | +5.7% | +2.1% | -2.1% |
HALO leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
HALO leads this category, winning 3 of 5 comparable metrics.
Valuation Metrics
At 25.5x trailing earnings, HALO trades at a 90% valuation discount to GNFT's 256.9x P/E. On an enterprise value basis, HALO's 8.3x EV/EBITDA is more attractive than GNFT's 73.1x.
| Metric | GNFTGenfit S.A. | AKROAkero Therapeutic… | MDGLMadrigal Pharmace… | HALOHalozyme Therapeu… |
|---|---|---|---|---|
| Market CapShares × price | $448M | $4.5B | $12.3B | $7.7B |
| Enterprise ValueMkt cap + debt − cash | $425M | $4.2B | $12.4B | $7.5B |
| Trailing P/EPrice ÷ TTM EPS | 256.88x | -14.57x | -41.62x | 25.46x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | 8.09x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | 1.11x |
| EV / EBITDAEnterprise value multiple | 73.07x | — | — | 8.34x |
| Price / SalesMarket cap ÷ Revenue | 5.75x | — | 12.80x | 5.50x |
| Price / BookPrice ÷ Book value/share | 5.59x | 4.89x | 19.91x | 165.47x |
| Price / FCFMarket cap ÷ FCF | 27.10x | — | — | 11.91x |
HALO leads this category, winning 3 of 5 comparable metrics.
Profitability & Efficiency
HALO leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
HALO delivers a 6.5% return on equity — every $100 of shareholder capital generates $6 in annual profit, vs $-50 for MDGL. AKRO carries lower financial leverage with a 0.05x debt-to-equity ratio, signaling a more conservative balance sheet compared to GNFT's 0.90x. On the Piotroski fundamental quality scale (0–9), GNFT scores 6/9 vs AKRO's 2/9, reflecting solid financial health.
| Metric | GNFTGenfit S.A. | AKROAkero Therapeutic… | MDGLMadrigal Pharmace… | HALOHalozyme Therapeu… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -23.0% | -30.6% | -50.2% | +6.5% |
| ROA (TTM)Return on assets | -9.0% | -29.1% | -25.4% | +12.5% |
| ROICReturn on invested capital | +4.5% | -55.3% | -29.4% | +73.4% |
| ROCEReturn on capital employed | +3.1% | -42.4% | -32.9% | +38.2% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 2 | 3 | 5 |
| Debt / EquityFinancial leverage | 0.90x | 0.05x | 0.59x | — |
| Net DebtTotal debt minus cash | -$20M | -$304M | $156M | -$134M |
| Cash & Equiv.Liquid assets | $82M | $340M | $199M | $134M |
| Total DebtShort + long-term debt | $62M | $36M | $354M | $0 |
| Interest CoverageEBIT ÷ Interest expense | -0.67x | -62.41x | -17.51x | 46.08x |
HALO leads this category, winning 6 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
Evenly matched — GNFT and MDGL and HALO each lead in 2 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MDGL five years ago would be worth $41,011 today (with dividends reinvested), compared to $13,704 for HALO. Over the past 12 months, GNFT leads with a +110.6% total return vs HALO's -7.1%. The 3-year compound annual growth rate (CAGR) favors HALO at 29.1% vs AKRO's 6.3% — a key indicator of consistent wealth creation.
| Metric | GNFTGenfit S.A. | AKROAkero Therapeutic… | MDGLMadrigal Pharmace… | HALOHalozyme Therapeu… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | +48.5% | — | -9.9% | -7.3% |
| 1-Year ReturnPast 12 months | +110.6% | +27.7% | +79.0% | -7.1% |
| 3-Year ReturnCumulative with dividends | +109.6% | +20.1% | +73.2% | +115.3% |
| 5-Year ReturnCumulative with dividends | +111.6% | +100.0% | +310.1% | +37.0% |
| 10-Year ReturnCumulative with dividends | -59.6% | +198.3% | +3921.5% | +570.7% |
| CAGR (3Y)Annualised 3-year return | +28.0% | +6.3% | +20.1% | +29.1% |
Evenly matched — GNFT and MDGL and HALO each lead in 2 of 6 comparable metrics.
Risk & Volatility
AKRO leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
AKRO is the less volatile stock with a 0.35 beta — it tends to amplify market swings less than GNFT's 0.95 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. AKRO currently trades 95.3% from its 52-week high vs HALO's 79.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | GNFTGenfit S.A. | AKROAkero Therapeutic… | MDGLMadrigal Pharmace… | HALOHalozyme Therapeu… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.95x | 0.35x | 0.57x | 0.56x |
| 52-Week HighHighest price in past year | $10.20 | $57.35 | $615.00 | $82.22 |
| 52-Week LowLowest price in past year | $3.00 | $37.28 | $265.00 | $47.50 |
| % of 52W HighCurrent price vs 52-week peak | +87.7% | +95.3% | +87.0% | +79.3% |
| RSI (14)Momentum oscillator 0–100 | 71.8 | 70.4 | 61.2 | 52.4 |
| Avg Volume (50D)Average daily shares traded | 4K | 0 | 310K | 1.4M |
AKRO leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: GNFT as "Buy", AKRO as "Buy", MDGL as "Buy", HALO as "Buy". Consensus price targets imply 45.3% upside for GNFT (target: $13) vs -11.4% for AKRO (target: $48).
| Metric | GNFTGenfit S.A. | AKROAkero Therapeutic… | MDGLMadrigal Pharmace… | HALOHalozyme Therapeu… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $13.00 | $48.40 | $705.67 | $78.33 |
| # AnalystsCovering analysts | 7 | 14 | 23 | 27 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | 1 | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | +4.5% |
Insufficient data to determine a leader in this category.
Key Takeaway
HALO leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). AKRO leads in 1 (Risk & Volatility). 1 tied.
Best OverallHalozyme Therapeutics, Inc. (HALO)Leads 3 of 6 categories
Loading custom metrics...
GNFT vs AKRO vs MDGL vs HALO: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is GNFT or AKRO or MDGL or HALO a better buy right now?
For growth investors, Madrigal Pharmaceuticals, Inc.
(MDGL) is the stronger pick with 432. 1% revenue growth year-over-year, versus 37. 6% for Halozyme Therapeutics, Inc. (HALO). Halozyme Therapeutics, Inc. (HALO) offers the better valuation at 25. 5x trailing P/E (8. 1x forward), making it the more compelling value choice. Analysts rate Genfit S. A. (GNFT) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — GNFT or AKRO or MDGL or HALO?
On trailing P/E, Halozyme Therapeutics, Inc.
(HALO) is the cheapest at 25. 5x versus Genfit S. A. at 256. 9x.
03Which is the better long-term investment — GNFT or AKRO or MDGL or HALO?
Over the past 5 years, Madrigal Pharmaceuticals, Inc.
(MDGL) delivered a total return of +310. 1%, compared to +37. 0% for Halozyme Therapeutics, Inc. (HALO). Over 10 years, the gap is even starker: MDGL returned +39. 2% versus GNFT's -59. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — GNFT or AKRO or MDGL or HALO?
By beta (market sensitivity over 5 years), Akero Therapeutics, Inc.
(AKRO) is the lower-risk stock at 0. 35β versus Genfit S. A. 's 0. 95β — meaning GNFT is approximately 172% more volatile than AKRO relative to the S&P 500. On balance sheet safety, Akero Therapeutics, Inc. (AKRO) carries a lower debt/equity ratio of 5% versus 90% for Genfit S. A. — giving it more financial flexibility in a downturn.
05Which is growing faster — GNFT or AKRO or MDGL or HALO?
By revenue growth (latest reported year), Madrigal Pharmaceuticals, Inc.
(MDGL) is pulling ahead at 432. 1% versus 37. 6% for Halozyme Therapeutics, Inc. (HALO). On earnings-per-share growth, the picture is similar: Genfit S. A. grew EPS 105. 2% year-over-year, compared to -29. 8% for Akero Therapeutics, Inc.. Over a 3-year CAGR, HALO leads at 28. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — GNFT or AKRO or MDGL or HALO?
Halozyme Therapeutics, Inc.
(HALO) is the more profitable company, earning 22. 7% net margin versus -30. 1% for Madrigal Pharmaceuticals, Inc. — meaning it keeps 22. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HALO leads at 58. 4% versus -31. 3% for MDGL. At the gross margin level — before operating expenses — GNFT leads at 99. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is GNFT or AKRO or MDGL or HALO more undervalued right now?
Analyst consensus price targets imply the most upside for GNFT: 45.
3% to $13. 00.
08Which pays a better dividend — GNFT or AKRO or MDGL or HALO?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is GNFT or AKRO or MDGL or HALO better for a retirement portfolio?
For long-horizon retirement investors, Halozyme Therapeutics, Inc.
(HALO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 56), +570. 7% 10Y return). Both have compounded well over 10 years (HALO: +570. 7%, GNFT: -59. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between GNFT and AKRO and MDGL and HALO?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: GNFT is a small-cap high-growth stock; AKRO is a small-cap quality compounder stock; MDGL is a mid-cap high-growth stock; HALO is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.